Jubilant Therapeutics
Pennsylvania, United States · Biopharma, Biotechnology, Health Care
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutic
Key facts
- Headquarters
- Pennsylvania, United States
- Employees
- 12
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- jubilanttx.com
- Company page
Recent activity at Jubilant Therapeutics
Leadership
- Daniel J. O’Connor, Chief Executive Officer
Verified email and direct lines for Jubilant Therapeutics’s decision-makers are on Fundz. See plans
Jubilant Therapeutics in the news
- Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer - prnewswire.com (Dec 05, 2025)
- The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils Halts Cancer Progression and Metastasis | Newswise - Newswise (Sep 07, 2022)
- Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor - prnewswire.com (Oct 25, 2024)
- Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026 - prnewswire.com (Sep 15, 2026)
- Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. and Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMO - prnewswire.com (Aug 16, 2021)
- Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC) - prnewswire.com (Jan 05, 2023)
- Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models - prnewswire.com (Apr 13, 2023)
- Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors - prnewswire.com (Feb 05, 2021)
Companies similar to Jubilant Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Jubilant Therapeutics: questions and answers
What does Jubilant Therapeutics do?
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutic
Where is Jubilant Therapeutics headquartered?
Jubilant Therapeutics is headquartered in Pennsylvania, United States.
How many employees does Jubilant Therapeutics have?
Jubilant Therapeutics has about 12 employees.
Who leads Jubilant Therapeutics?
Daniel J. O’Connor is a Chief Executive Officer at Jubilant Therapeutics.
What is the latest news on Jubilant Therapeutics?
On Dec 02, 2025, Jubilant Pharmova Appoints Daniel J. O’Connor as Chief Executive Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy